| Title: |
Triple Nucleoside Combination Zidovudine/Lamivudine/Abacavir versus Zidovudine/Lamivudine/Nelfinavir as First-Line Therapy in HIV-1-Infected Adults: A Randomized Trial |
| Authors: |
Matheron, Sophie; Descamps, Diane; Boué, François; Livrozet, Jean-Michel; Lafeuillade, Alain; Aquilina, Christian; Troisvallets, Didier; Goetschel, Agnès; Brun-Vezinet, Françoise; Mamet, Jean-Philippe; Thiaux, Cécile; Allegre, T; Bataille, P; Bazin, C; Bentata, M; Bergmann, JF; Beytout, J; Bicart-See, A; Bodard, L; Brottier-Mancini, E; Caron, F; Cassuto, JP; Chousterman, M; Counillon, E; Delfraissy, JF; Dellamonica, P; Doll, J; Faller, JP; Gallais, H; Garre, M; Gastaut, JA; Gilquin, J; Herson, S; Hoen, B; Jarousse, B.; Katlama, C; Lacoste, D; Lange, JM; Lecomte, I; Lepeu, G; Lucht, F; Malkin, JE; Massip, P; Mechali, D; Molina, JM; Mouton, Y; Pathe, JP; Peyramond, D; Philibert, P; Plaisance, N |
| Source: |
Antiviral Therapy ; volume 8, issue 2, page 163-171 ; ISSN 1359-6535 2040-2058 |
| Publisher Information: |
SAGE Publications |
| Publication Year: |
2003 |
| Description: |
Objective To compare the efficacy and safety of a triple nucleoside combination to a protease inhibitor-containing triple regimen as first-line antiretroviral therapy (ART) in HIV-1-infected patients. Design Open-label study in HIV-1-infected ART-naive adults, randomized to receive either Combivir® (lamivudine 150 mg/zidovudine 300 mg twice daily) + abacavir (300 mg twice daily), or Combivir® + nelfinavir (750 mg every 8 h) for 48 weeks. Plasma HIV-1 RNA, CD4 cell count and adverse events were assessed at baseline and weeks 4, 8, 16, 24, 32, 40 and 48. Results 195 subjects (131 men, 64 women), median age 34 years, were randomized: 98 received combivir/abacavir and 97 combivir/nelfinavir. Baseline median plasma HIV-1 RNA was 4.2 log 10 copies/ml [Interquartile range (IQR): 3.7-4.5.2] and 4.1 log 10 copies/ml (IQR: 3.8–4.6), respectively. Baseline median CD4 cell count was 387 cells/mm 3 (IQR: 194–501) and 449 cells/mm 3 (IQR: 334–605), respectively. Nine patients (3 vs 6, respectively) did not start treatment or did not have any available efficacy data. At week 48, using the intent to treat analysis (switch/missing equals failure), plasma HIV-1 RNA was |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1177/135965350300800211 |
| Availability: |
https://doi.org/10.1177/135965350300800211; https://journals.sagepub.com/doi/pdf/10.1177/135965350300800211 |
| Rights: |
https://journals.sagepub.com/page/policies/text-and-data-mining-license |
| Accession Number: |
edsbas.36F2AEDC |
| Database: |
BASE |